OBJECTIVE: This study aimed to evaluate remission in @entity1 with early @entity309 treated by conventional DMARDs and to identify its possible predictor factors. METHODS: @entity1 with early @entity309 (<12 months) were enrolled in a 2-year follow-up study. Standard evaluation completed at baseline and at 24 months included clinical, laboratory, functional and structural assessment. Clinical remission after 2 years of follow-up was defined when DAS28 was less than 2.6. Possible predictor factors for remission were analyzed. RESULTS: Fifty-one @entity1 (88.2% @entity1 , mean age of 46.9 [24-72] years, mean disease duration of 24 [6-48] weeks) were enrolled in this study. The delay in referral for specialist care was 140 [7-420] days. Rheumatoid factor, anti-CCP, @entity1533 *01 and @entity1533 *04 alleles were present respectively in 62.5, 56.6, 11.8, and 45.1% of @entity1 . At 24 months, 77.2% received a median dose of 5 (0-8) mg/day of @entity229 and 65.2% was taking @entity1499 ( @entity1500 ). 13.6% of @entity1 had stopped their DMARD because of socioeconomic difficulties. At 24 months, we noted a significant improvement of morning @entity2693 , @entity158 score, swollen joint count, ESR, CRP, DAS28 and HAQ scores. Remission at 2 years was noted in 34.8% of @entity1 and was significantly associated in univariate but not in multivariate analysis to male sex (P=0.02) and to short delay in referral for specialist (P=0.03). CONCLUSION: In this cohort of early @entity309 @entity1 treated with conventional DMARDs, especially with @entity1499 in monotherapy, remission at 2-year of follow-up was obtained in one third of @entity1 . No predictor factors of remission were found out. These results should be verified by further studies.

Remission in early XXXX treated with conventional DMARDs. Results of a two-year follow-up study of El Ayachi Moroccan cohort.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity2693 :: ('MESH:C566112', 'Disease') :: ['stiffness'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity309 :: ('MESH:D001172', 'Disease') :: ['RA'] @entity1533 :: ('3123', 'Gene') :: ['DRB1', 'HLA-DRB1']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
